SYSTEMATIC REVIEW article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1643133
This article is part of the Research TopicColorectal Cancer Immunotherapy and Immune MechanismsView all 19 articles
Efficacy and Safety of First-line Targeted and Immunotherapy for Metastatic Colorectal Cancer: A Network Meta-Analysis
Provisionally accepted
- Fourth Hospital of Hebei Medical University, Shijiazhuang, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: As targeted therapies and immunotherapy become increasingly prevalent in treating metastatic colorectal cancer (mCRC), comparative analyses are essential to determine the most effective and safe treatment combinations. This study aims to compare and rank the efficacy and safety profiles of first-line systemic treatments for mCRC. Methods: This network meta-analysis was conducted in compliance with PRISMA guidelines, reviewing randomized controlled trials from PubMed, Embase, Web of Science, Cochrane Library, and ClinicalTrials.gov through March 2024. A network meta-analysis is conducted using a Bayesian random effects mode. After the data was extracted, data analysis was conducted in gemtc R. The primary outcomes measured were overall survival (OS), progression-free survival (PFS), and the incidence of adverse events (AEs) graded ≥3.The Cochrane risk-of-bias assessment tool was used to evaluate the quality of each study. Results: A total of 61 RCTs involving 20,579 patients were included. The results showed that FOLFOXIRI combined with bevacizumab and atezolizumab significantly improved PFS and OS, with HRs for PFS and OS of (HR:0.19, 95% CI: 0.11–0.33), (HR:0.48, 95% CI: 0.30–0.78), respectively. The incidence of ≥Grade 3 AEs was high, but no new fatal treatment-related AEs were observed, and the safety of this regimen was manageable. FOLFOXIRI in combination with anti-EGFR monoclonal antibody regimens showed significant PFS and OS improvements in the RAS/BRAF wild-type subgroup. For the subgroup of patients aged ≥70 years, thetrifluorouridine-tipiracil plus bevacizumab regimen also had some advantage in PFS and OS. Although the incidence of Grade ≥3 AEs was higher, the incidence of AEs was similar across age groups and well tolerated in this regimen, and it was more suitable for elderly cancer patients. Discussion: These findings underscore the importance of integrating targeted drugs and immunotherapy in first-line mCRC treatments, highlighting significant differences in efficacy and safety profiles that can guide therapeutic decisions.
Keywords: Metastatic colorectal cancer, first-line therapy, Targeted drugs, Immunotherapy, Network meta-analysis
Received: 08 Jun 2025; Accepted: 29 Sep 2025.
Copyright: © 2025 Huo, Yue, Yang, Sun, Wang, Liu, Liu, Feng and Liang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Jiang Liu, 46500785@hebmu.edu.cn
Rui Feng, 48100995@hebmu.edu.cn
Ping Liang, 48001098@hebmu.edu.cn
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.